Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMALCO semaglutide trial for alcohol use disorder with obesity
2023-503371-25-00Phase 2Completed
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in alcohol use disorder (AUD) and obesity comparing Semaglutide arm with Saline control arm (2 arms). Primary endpoint: Change in percentage of heavy drinking days. Started Jun 2023; status: completed.
02
Drugs
semaglutidesaline
03
Conditions
alcohol use disorder (AUD)obesity
Beyond the preview
Go deeper on 2023-503371-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503371-25-00.